Avantect Pancreatic Cancer Test
Use
The Avantect Pancreatic Cancer Test is designed for the early detection of pancreatic cancer, particularly for individuals at elevated risk. Early detection is critical since diagnosing pancreatic cancer at its earliest stages significantly improves survival rates. The test helps to identify pancreatic cancer signals at early stages, supporting earlier navigation of care and improving outcomes.
Special Instructions
Not provided.
Limitations
The test is not a definitive diagnostic tool for pancreatic cancer. Results should be considered in context with other clinical criteria, as imaging, biopsies, and additional blood tests are usually required for a conclusive diagnosis. The test may yield false-positive or false-negative results, meaning cancer may still be present even if not detected by the test, and vice versa.
Methodology
Composite
Biomarkers
5-hydroxymethylcytosine
AnalyteGenomic Features
AnalyteGlycan Biomarkers
Analyte
Result Turnaround Time
14 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Request a collection kit, collect the blood sample, and ship it.